Seattle Times – Delafield Hambrecht, a Seattle investment firm, is working to raise $100 million for a hedge fund focused on biotechnology stocks.<\/p>\n
Launched earlier this month, the fund will be managed by Quynh Pham, a lauded stock-picker during her years with Delafield’s research department. She said the Delafield Hambrecht Biotechnology Fund initially will only invest in public companies and will be “geography agnostic.”<\/p>\n
“Regardless of where companies are situated, we’re really looking for good investment ideas,” Pham said.<\/p>\n
She’s keeping details of the investment strategy close to the vest.<\/p>\n
Delafield Hambrecht shuttered its brokerage department, including stock trading and research, in December. The firm, which split off from San Francisco-based WR Hambrecht in early 2002, continues to offer asset management and investment banking.<\/p>\n